Passage Bio Stock Net Income
| PASG Stock | USD 0.60 0.01 1.69% |
Passage Bio fundamentals help investors to digest information that contributes to Passage Bio's financial success or failures. It also enables traders to predict the movement of Passage Stock. The fundamental analysis module provides a way to measure Passage Bio's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Passage Bio stock.
| Last Reported | Projected for Next Year | ||
| Net Loss | -101.1 M | -106.2 M | |
| Net Loss | -122.5 M | -128.6 M | |
| Net Loss | -91.9 M | -96.4 M | |
| Net Loss | (2.14) | (2.25) | |
| Net Income Per E B T | 1.16 | 1.17 |
Passage | Net Income |
Passage Bio Company Net Income Analysis
Passage Bio's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Passage Bio Net Income | (102.06 M) |
Most of Passage Bio's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Passage Bio is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Passage Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Passage Bio is extremely important. It helps to project a fair market value of Passage Stock properly, considering its historical fundamentals such as Net Income. Since Passage Bio's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Passage Bio's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Passage Bio's interrelated accounts and indicators.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Passage Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Passage Bio reported net income of (102.06 Million). This is 129.91% lower than that of the Biotechnology sector and 245.71% lower than that of the Health Care industry. The net income for all United States stocks is 117.87% higher than that of the company.
Passage Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Passage Bio's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Passage Bio could also be used in its relative valuation, which is a method of valuing Passage Bio by comparing valuation metrics of similar companies.Passage Bio is currently under evaluation in net income category among its peers.
Passage Bio Institutional Holders
Institutional Holdings refers to the ownership stake in Passage Bio that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Passage Bio's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Passage Bio's value.| Shares | Fiduciary Trust Co | 2024-09-30 | 215 K | Millennium Management Llc | 2024-09-30 | 163.9 K | Rbf Llc | 2024-09-30 | 142.8 K | State Street Corp | 2024-09-30 | 123.9 K | Two Sigma Investments Llc | 2024-09-30 | 98 K | Shay Capital Llc | 2024-09-30 | 92.3 K | Landscape Capital Management,llc | 2024-09-30 | 53.9 K | Northern Trust Corp | 2024-09-30 | 40.3 K | Engineers Gate Manager Lp | 2024-09-30 | 34.8 K | Orbimed Advisors, Llc | 2024-09-30 | 9.8 M | Vestal Point Capital Lp | 2024-09-30 | 6.1 M |
Passage Fundamentals
| Return On Equity | -0.64 | ||||
| Return On Asset | -0.34 | ||||
| Current Valuation | (21.95 M) | ||||
| Shares Outstanding | 61.77 M | ||||
| Shares Owned By Insiders | 0.49 % | ||||
| Shares Owned By Institutions | 59.68 % | ||||
| Number Of Shares Shorted | 3.85 M | ||||
| Price To Book | 0.51 X | ||||
| EBITDA | (98.34 M) | ||||
| Net Income | (102.06 M) | ||||
| Cash And Equivalents | 239.25 M | ||||
| Cash Per Share | 4.39 X | ||||
| Total Debt | 26.29 M | ||||
| Debt To Equity | 0.11 % | ||||
| Current Ratio | 9.23 X | ||||
| Book Value Per Share | 2.02 X | ||||
| Cash Flow From Operations | (78.26 M) | ||||
| Short Ratio | 6.61 X | ||||
| Earnings Per Share | (1.17) X | ||||
| Target Price | 8.0 | ||||
| Number Of Employees | 58 | ||||
| Beta | 1.2 | ||||
| Market Capitalization | 37.06 M | ||||
| Total Asset | 150.54 M | ||||
| Retained Earnings | (594.47 M) | ||||
| Working Capital | 101.62 M | ||||
| Current Asset | 144.91 M | ||||
| Current Liabilities | 3.09 M | ||||
| Net Asset | 150.54 M |
About Passage Bio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Passage Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Passage Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Passage Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin | |
| ADA | Cardano | |
| XRP | XRP |
Check out Passage Bio Piotroski F Score and Passage Bio Altman Z Score analysis. For more detail on how to invest in Passage Stock please use our How to Invest in Passage Bio guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Passage Bio. If investors know Passage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Passage Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Passage Bio is measured differently than its book value, which is the value of Passage that is recorded on the company's balance sheet. Investors also form their own opinion of Passage Bio's value that differs from its market value or its book value, called intrinsic value, which is Passage Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Passage Bio's market value can be influenced by many factors that don't directly affect Passage Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Passage Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Passage Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Passage Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.